TAM
ATYR

Tiverton Asset Management’s aTyr Pharma ATYR Stock Holding History

Tiverton Asset Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-6,808
Closed -$205K – 208
2016
Q4 		$205K Sell
6,808
-8,460
-55% -$347K 0.01% 189
2016
Q3 		$680K Sell
15,268
-9,571
-39% -$414K 0.05% 147
2016
Q2 		$967K Sell
24,839
-5,529
-18% -$257K 0.04% 141
2016
Q1 		$1.68M Sell
30,368
-2,846
-9% -$216K 0.06% 142
2015
Q4 		$4.57M Sell
33,214
-517
-2% -$73.6K 0.15% 114
2015
Q3 		$4.84M Buy
33,731
+1,588
+5% +$362K 0.11% 121
2015
Q2 		$8.33M Buy
+32,143
New +$9.98M 0.17% 118

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GHCM
Glen Harbor Capital Management San Diego, California $4.82B AUM 4.69% 1-Year Est. Return
MCIM
Meadow Creek Investment Management Atlanta, Georgia $5.09B AUM 5.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tiverton Asset Management's ATYR Position: Q1 2017 in Review

Tiverton Asset Management sold out of aTyr Pharma (ATYR) in Q1 2017, closing a stake of 6,808 shares — an estimated $205K sold.

Tiverton Asset Management first reported a position in ATYR in Q2 2015 and held it in 7 quarters. The position peaked at $8.33M in Q2 2015. 39 funds tracked by Wall St. Rank hold ATYR as of Q1 2017.

  • Tiverton Asset Management reported no remaining aTyr Pharma position as of Q1 2017 after selling out during the quarter.
  • Tiverton Asset Management sold 6,808 aTyr Pharma shares in Q1 2017, an estimated $205K.
  • Tiverton Asset Management first reported a position in aTyr Pharma in Q2 2015 and held it in 7 quarters.
  • Tiverton Asset Management's aTyr Pharma position peaked at $8.33M in Q2 2015.
  • 39 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2017.

Based on Tiverton Asset Management's 13F filing for Q1 2017, filed 15 May 2017.